Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Two Dupilumab Formulations in Healthy Volunteers
NCT05976360Phase 1Completed
- Sponsor
- Sanofi
- Start
- Nov 2014
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dupilumab in atopic dermatitis (AD) and asthma (2 arms), sponsored by Sanofi. Primary endpoints: Maximum serum concentration observed, Time to reach Cmax and 1 more. Started Nov 2014; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)asthma
Beyond the preview
Go deeper on NCT05976360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05976360.